Organ-on-Chip-Guided Evaluation of Nanocarrier Transport Across Biological Barriers: A Critical Review of Predictive Models for Translational Drug Delivery
Оценка транспорта нанопереносчиков через биологические барьеры с использованием орган-на-чипе: критический обзор прогностических моделей для трансляционной доставки лекарственных средств
2026-10-06
SCID: 54.1/es2hsndc
Discuss with AI
biological barriersin vitro–in vivo extrapolationnanocarrier transportorgan-on-chip systemsphysiologically based pharmacokinetic modeling
Figures from the paper
Abstract (AI)
Drug delivery systems based on nanocarriers can cross biological barriers to regulate the movement of molecules and particles between different physiological compartments, which plays an important role in therapeutic performance.Two-dimensional cell cultures and animal models are important sources of preclinical information but often do not replicate the dynamic mechanical, cellular, and structural properties that dictate nanocarrier transport in humans.Organ-on-chip systems are sophisticated microphysiological systems that can mimic tissue interfaces in a controlled environment with fluid flow, shear stress, multicellular structure, and extracellular matrix.These systems offer novel possibilities to study permeability, cellular uptake, transcytosis, barrier accumulation, and barrier-associated toxicity of nanocarriers in physiologically relevant environments.This review critically summarizes organ-on-chip studies on the transport of nanocarriers across key biological barriers such as the blood-brain, intestinal, pulmonary, placental, vascular/tumor, renal, and skin barriers.Specific focus is given to the physicochemical factors that influence the transport of nanocarriers, the quantitative evaluation of barriers, predictive performance, and translational relevance.The use of organ-on-chip information in physiologically based pharmacokinetic modelling, in-vitro-in-vivo extrapolation and with the development of artificial intelligence is also addressed.Despite the standardization, reproducibility and material selection, scaling and validation hurdles, organ-on-chip technology seems to be a bridge between experimental nanomedicine and drug-delivery prediction in humans.
Key Findings
1
Nanocarrier physicochemical properties and quantitative barrier measurements are central to evaluating predictive performance and translational relevance.
2
Organ-on-chip data can support physiologically based pharmacokinetic modeling, in-vitro-in-vivo extrapolation, and artificial-intelligence-assisted drug-delivery prediction, but standardization, reproducibility, material selection, scaling, and validation remain major hurdles.
3
Organ-on-chip models enable physiologically relevant assessment of nanocarrier permeability, cellular uptake, transcytosis, barrier accumulation, and barrier-associated toxicity.
4
Organ-on-chip systems more realistically reproduce the dynamic mechanical, cellular, structural, and extracellular-matrix properties governing nanocarrier transport than conventional two-dimensional cultures and animal models.
5
The review synthesizes nanocarrier transport studies across blood-brain, intestinal, pulmonary, placental, vascular/tumor, renal, and skin barriers.
Research Object
Nanocarrier transport across organ-on-chip models of key biological barriers
Research Subject
Permeability, cellular uptake, transcytosis, barrier accumulation, toxicity, physicochemical determinants, and predictive and translational performance of nanocarrier transport
Publication Details
Publication Date
2026-10-06
Journal
Publisher
ISSN
Cited by
0
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest